Formulation Development
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD With AIM Biologicals Program
Aeterna Zentaris Inc. recently announced its Autoimmunity Modifying (AIM) Biologicals program has achieved preclinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder (NMOSD)…
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, a Type of Brain Cancer That Affects Predominantly Pediatric Patients
Nuvectis Pharma, Inc. recently announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12, 2022, at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists….
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
Veralox Therapeutics recently announced favorable results from the company's Phase 1 clinical program for VLX-1005, a novel 12-LOX inhibitor being developed for the treatment and…
MERXIN & Gerresheimer Worked Successfully Together to Realize the Shortest Possible Time to Market for the MERXIN MRX003 Capsule DPI
Gerresheimer has assumed responsibility for the industrialization of a dry powder inhaler for the treatment of respiratory ailments for MERXIN (United Kingdom), a company that…
Vyluma & Laboratoires Théa Enter Licensing Agreement for the Registration & Commercialization of NVK002 in Canada, Mexico & Select South American Countries
Vyluma, Inc. and Laboratoires Théa recently announced they have recently entered into an exclusive licensing agreement for the registration and commercialization of NVK002 in Canada,…
Pike Therapeutics Announces Positive Pharmacokinetic Animal Study Results & Unexpected Benefits for its Proprietary Weekly CBD Continuous Transdermal Delivery Technology
Pike Therapeutics Inc. has recently completed a preliminary pharmacokinetic rabbit study with its CBD formulations that yielded positive early results. This study demonstrated….
Exavir Therapeutics Announces Preclinical Data for Ultra-Long-Acting Dolutegravir Prodrug XVIR-120
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-120, an investigational agent being developed as a long-acting injectable antiviral for HIV….
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
Olema Pharmaceuticals, Inc. recently announced clinical development progress for OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development…
Replicate Bioscience & Curia Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA
Replicate Bioscience and Curia, formerly AMRI, recently announced they will collaborate on a robust development platform for Replicate’s srRNA therapeutics. The strategic collaboration unites….
First Patient Dosed in Second Phase 2 Add-on Ketamine Trial in Treatment-Resistant Depression
HMNC Brain Health, together with Develco Pharma, recently announced the dosing of the first patient in their second Phase 2 trial with oral prolonged-release Ketamine…
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the…
Editas Medicine & Immatics Enter Strategic Research Collaboration & Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies & Gene Editing for the Treatment of Cancer
Editas Medicine, Inc. and Immatics N.V. recently announced the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and….
Apellis & Sobi Announce First Patient Dosed in Phase 3 Study of Pegcetacoplan for IC-MPGN & C3G, Rare Kidney Diseases With High Unmet Medical Need
Apellis Pharmaceuticals, Inc. and Sobi recently announced the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy,…
ProteoGenix, Aseem Healthcare & Trident Biopharm Solutions Announce New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2
ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions recently announced the development of a new antibody cocktail effective against major variants of SARS-CoV-2. The cocktail of…
Evonik Launches New Peptide to Boost Productivity of Cell-Culture-Based Biopharmaceuticals
Evonik now offers a highly pure cystine peptide to address challenges in the formulation of cell culture media and processes used in the development and…
SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022?
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities
Berkeley Lights, Inc. and Curia recently announced Curia’s adoption of The Beacon Optofluidic system and workflows from Berkeley Lights to accelerate….
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
Yumanity Therapeutics, Inc. recently announced it has entered into definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase….
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next-Generation Core Inhibitor
Assembly Biosciences, Inc. recently announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733 (3733). 3733 has demonstrated…
Jubilant HollisterStier Enters Cooperative Agreement With US Government to Expand Critical Vaccine Manufacturing Capacity
Jubilant Pharmova Limited recently announced that Jubilant Pharma Limited, a wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based….
